Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Myriad Genetics, |
RCV003335721 | SCV004044977 | pathogenic | Juvenile polyposis syndrome | 2023-05-26 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. |
Ambry Genetics | RCV004604940 | SCV005095231 | pathogenic | Hereditary cancer-predisposing syndrome | 2024-04-03 | criteria provided, single submitter | clinical testing | The p.Q117* pathogenic mutation (also known as c.349C>T), located in coding exon 4 of the BMPR1A gene, results from a C to T substitution at nucleotide position 349. This changes the amino acid from a glutamine to a stop codon within coding exon 4. This variant has been detected in patients with juvenile polyposis syndrome (JPS) (Sayed MG et al. Ann Surg Oncol, 2002 Nov;9:901-6; Aretz S et al. J Med Genet, 2007 Nov;44:702-9). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |